Vutrisiran sodium

武特里西兰

Report date: 2025/12/02 14:18:09
NME

Base Information

Drug NameVutrisiran sodium
Drug Alias Name夫曲赛仑VutrisiranAMVUTTRAALN-TTRSC02ALN‑TTRsc02 +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceTransthyretin inhibitors
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisAmyloidosis, FamilialCardiomyopathies +[4] 
Global Approved IndicationsTransthyretin amyloidosisAmyloid Neuropathies, Familial
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/06/13
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlnylam Japan KkRoyalty Pharma PLCSanofi +[5] 
Inactive CompaniesN/A
Active IndicationsTransthyretin amyloidosisAmyloidosis, FamilialCardiomyopathies +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN07XX18
Related LinksWikipediaDrugBankKEGG